Neuralstem Company Profile (NASDAQ:CUR)

About Neuralstem (NASDAQ:CUR)

Neuralstem logoNeuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company's technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company's NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CUR
  • CUSIP: N/A
  • Web: www.neuralstem.com
Capitalization:
  • Market Cap: $16.6 million
  • Outstanding Shares: 12,117,000
Average Prices:
  • 50 Day Moving Avg: $1.18
  • 200 Day Moving Avg: $3.98
  • 52 Week Range: $0.22 - $6.60
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.61
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $16,246.00
  • Price / Sales: 1,021.81
  • Book Value: $0.64 per share
  • Price / Book: 2.14
Profitability:
  • EBIDTA: ($18,670,000.00)
  • Net Margins: -198,573.91%
  • Return on Equity: -321.78%
  • Return on Assets: -127.53%
Debt:
  • Current Ratio: 5.08%
  • Quick Ratio: 5.08%
Misc:
  • Average Volume: 418,030 shs.
  • Beta: 2.06
  • Short Ratio: 2.34
 

Frequently Asked Questions for Neuralstem (NASDAQ:CUR)

What is Neuralstem's stock symbol?

Neuralstem trades on the NASDAQ under the ticker symbol "CUR."

How were Neuralstem's earnings last quarter?

Neuralstem, Inc. (NASDAQ:CUR) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.39) EPS for the quarter, beating analysts' consensus estimates of ($9.49) by $9.10. Neuralstem had a negative net margin of 198,573.91% and a negative return on equity of 321.78%. View Neuralstem's Earnings History.

When will Neuralstem make its next earnings announcement?

Neuralstem is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Neuralstem.

Where is Neuralstem's stock going? Where will Neuralstem's stock price be in 2017?

3 brokers have issued 12 month target prices for Neuralstem's stock. Their forecasts range from $1.20 to $4.00. On average, they anticipate Neuralstem's stock price to reach $2.79 in the next year. View Analyst Ratings for Neuralstem.

Are investors shorting Neuralstem?

Neuralstem saw a decrease in short interest in August. As of August 15th, there was short interest totalling 673,010 shares, a decrease of 34.7% from the July 31st total of 1,030,661 shares. Based on an average trading volume of 549,688 shares, the short-interest ratio is presently 1.2 days. Currently, 7.2% of the shares of the stock are short sold.

Who are some of Neuralstem's key competitors?

Who are Neuralstem's key executives?

Neuralstem's management team includes the folowing people:

  • Richard J. Daly, Chairman of the Board, President, Chief Executive Officer, Interim Principal Financial and Accounting Officer
  • Scott V. Ogilvie, Independent Director
  • William C. Oldaker, Independent Director
  • Sandford D. Smith, Independent Director
  • Stanley I. Westreich, Independent Director

Who owns Neuralstem stock?

Neuralstem's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.90%), Alethea Capital Management LLC (2.76%), Blair William & Co. IL (0.73%), National Asset Management Inc. (0.19%) and Northern Trust Corp (0.17%). Company insiders that own Neuralstem stock include Jones Jonathan Brian Lloyd, Karl Johe and Richard J Daly. View Institutional Ownership Trends for Neuralstem.

Who bought Neuralstem stock? Who is buying Neuralstem stock?

Neuralstem's stock was acquired by a variety of institutional investors in the last quarter, including Alethea Capital Management LLC, Blair William & Co. IL, Vanguard Group Inc. and National Asset Management Inc.. Company insiders that have bought Neuralstem stock in the last two years include Jones Jonathan Brian Lloyd and Richard J Daly. View Insider Buying and Selling for Neuralstem.

How do I buy Neuralstem stock?

Shares of Neuralstem can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neuralstem's stock price today?

One share of Neuralstem stock can currently be purchased for approximately $1.37.


MarketBeat Community Rating for Neuralstem (NASDAQ CUR)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  119 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  185
MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Neuralstem (NASDAQ:CUR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.79 (103.89% upside)

Analysts' Ratings History for Neuralstem (NASDAQ:CUR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/16/2017S&P Equity ResearchLower Price Target$3.69 -> $3.18N/AView Rating Details
11/10/2016Roth CapitalReiterated RatingBuy$1.20N/AView Rating Details
11/7/2016AegisInitiated CoverageBuyN/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$4.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Neuralstem (NASDAQ:CUR)
Earnings by Quarter for Neuralstem (NASDAQ:CUR)
Earnings History by Quarter for Neuralstem (NASDAQ CUR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.50)N/AView Earnings Details
8/8/2017Q2 2017($9.49)($0.39)ViewN/AView Earnings Details
11/8/2016Q3($0.03)($0.05)ViewN/AView Earnings Details
8/11/2016Q2($0.05)($0.04)$2.50 million$2.50 millionViewN/AView Earnings Details
5/9/2016Q1($0.06)($0.07)ViewN/AView Earnings Details
3/14/2016Q4($0.07)($0.05)ViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.06)ViewN/AView Earnings Details
8/10/2015Q2($0.06)($0.06)ViewN/AView Earnings Details
5/8/2015Q115($0.07)($0.06)$2.92 millionViewN/AView Earnings Details
4/20/2015($0.07)($0.06)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.05)($0.06)$0.01 millionViewN/AView Earnings Details
11/7/2014Q314($0.05)($0.05)$0.01 millionViewN/AView Earnings Details
8/8/2014Q214($0.05)($0.08)$0.10 million$0.01 millionViewN/AView Earnings Details
5/12/2014Q114($0.05)($0.04)$0.35 million$0.00 millionViewN/AView Earnings Details
3/10/2014Q4 2013($0.06)($0.04)ViewN/AView Earnings Details
11/11/2013Q3($0.04)($0.09)ViewN/AView Earnings Details
8/9/2013Q213($0.05)($0.09)$0.08 million$0.00 millionViewN/AView Earnings Details
11/9/2012Q312($0.04)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Neuralstem (NASDAQ:CUR)
Current Year EPS Consensus Estimate: $-2.26 EPS
Next Year EPS Consensus Estimate: $-2.24 EPS

Dividends

Dividend History for Neuralstem (NASDAQ:CUR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Neuralstem (NASDAQ:CUR)
Insider Ownership Percentage: 19.25%
Institutional Ownership Percentage: 7.33%
Insider Trades by Quarter for Neuralstem (NASDAQ:CUR)
Institutional Ownership by Quarter for Neuralstem (NASDAQ:CUR)
Insider Trades by Quarter for Neuralstem (NASDAQ:CUR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/17/2017Richard J DalyCEOBuy7,500$4.00$30,000.00View SEC Filing  
3/24/2017Jones Jonathan Brian LloydCFOBuy5,455$5.50$30,002.50View SEC Filing  
2/24/2017Richard J DalyCEOBuy2,591$3.86$10,001.26View SEC Filing  
1/25/2017Richard J DalyCEOBuy2,841$3.52$10,000.32View SEC Filing  
12/23/2016Richard J DalyCEOBuy32,259$0.31$10,000.29View SEC Filing  
11/25/2016Richard J DalyCEOBuy35,715$0.28$10,000.20View SEC Filing  
10/25/2016Richard J DalyCEOBuy35,715$0.28$10,000.20View SEC Filing  
9/23/2016Richard J DalyCEOBuy31,250$0.32$10,000.00View SEC Filing  
11/16/2015Karl JoheInsiderSell25,000$1.09$27,250.00View SEC Filing  
11/9/2015Karl JoheInsiderSell25,000$1.18$29,500.00View SEC Filing  
11/2/2015Karl JoheInsiderSell25,000$1.17$29,250.00View SEC Filing  
10/26/2015Karl JoheInsiderSell25,000$1.13$28,250.00View SEC Filing  
10/19/2015Karl JoheInsiderSell25,000$1.23$30,750.00View SEC Filing  
10/12/2015Karl JoheInsiderSell25,000$1.31$32,750.00View SEC Filing  
10/5/2015Karl JoheInsiderSell25,000$1.26$31,500.00View SEC Filing  
9/28/2015Karl JoheInsiderSell25,000$1.64$41,000.00View SEC Filing  
9/21/2015Karl JoheInsiderSell25,000$1.52$38,000.00View SEC Filing  
9/2/2014Karl JoheInsiderSell6,000$4.09$24,540.00View SEC Filing  
8/1/2014Karl JoheInsiderSell6,000$2.78$16,680.00View SEC Filing  
7/1/2014Karl JoheInsiderSell6,000$4.17$25,020.00View SEC Filing  
6/2/2014Karl JoheInsiderSell6,000$4.25$25,500.00View SEC Filing  
5/5/2014William Clyde OldakerDirectorBuy15,235$3.50$53,322.50View SEC Filing  
4/22/2014Richard GarrCEOSell7,000$4.25$29,750.00View SEC Filing  
4/1/2014Karl JoheInsiderSell6,000$4.11$24,660.00View SEC Filing  
3/20/2014Karl JoheInsiderSell6,000$4.04$24,240.00View SEC Filing  
10/18/2013Karl JoheInsiderSell10,000$2.44$24,400.00View SEC Filing  
9/20/2013Karl JoheInsiderSell10,000$2.62$26,200.00View SEC Filing  
9/19/2013Karl JoheInsiderSell10,000$2.61$26,100.00View SEC Filing  
8/20/2013Karl JoheInsiderSell20,000$1.55$31,000.00View SEC Filing  
7/22/2013Karl JoheInsiderSell12,800$1.62$20,736.00View SEC Filing  
6/20/2013Karl JoheInsiderSell12,800$1.40$17,920.00View SEC Filing  
6/7/2013Richard GarrCEOSell6,000$1.42$8,520.00View SEC Filing  
5/20/2013Karl JoheInsiderSell12,800$1.51$19,328.00View SEC Filing  
2/25/2013Richard GarrCEOSell12,000$1.15$13,800.00View SEC Filing  
11/20/2012Karl JoheInsiderSell12,800$1.00$12,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Neuralstem (NASDAQ:CUR)
Latest Headlines for Neuralstem (NASDAQ:CUR)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 4:41 PM
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : September 12, 2017
finance.yahoo.com - September 11 at 11:28 PM
thestreet.com logoIntra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers - TheStreet.com
www.thestreet.com - September 7 at 10:45 PM
streetinsider.com logoNeuralstem (CUR) Reports Issuance of Two US Patents - StreetInsider.com
www.streetinsider.com - September 7 at 10:45 PM
streetinsider.com logoNeuralstem (CUR) Reports Issuance of Two U.S. Patents
www.streetinsider.com - September 7 at 5:44 PM
finance.yahoo.com logoNeuralstem Announces Issuance of Two U.S. Patents
finance.yahoo.com - September 7 at 5:44 PM
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 10:34 PM
americanbankingnews.com logoNeuralstem, Inc. (CUR) Short Interest Update
www.americanbankingnews.com - August 29 at 1:06 AM
finance.yahoo.com logoNeuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:51 PM
americanbankingnews.com logoHead-To-Head Review: Neuralstem (CUR) & AMAG Pharmaceuticals (AMAG)
www.americanbankingnews.com - August 22 at 8:26 PM
americanbankingnews.com logoNeuralstem, Inc. (CUR) Issues Earnings Results, Beats Expectations By $9.10 EPS
www.americanbankingnews.com - August 9 at 5:54 PM
nasdaq.com logoNeuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical and Business Update
www.nasdaq.com - August 8 at 10:21 PM
finance.yahoo.com logoNeuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical and Business Update
finance.yahoo.com - August 8 at 5:20 PM
finance.yahoo.com logoNeuralstem reports 2Q loss
finance.yahoo.com - August 8 at 5:20 PM
seekingalpha.com logoNeuralstem Is Doomed - Neuralstem, Inc. (NYSEMKT:CUR ... - Seeking Alpha
seekingalpha.com - August 3 at 7:03 PM
globenewswire.com logoNeuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment ... - GlobeNewswire (press release)
globenewswire.com - August 2 at 11:34 PM
nasdaq.com logoNeuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment ... - Nasdaq
www.nasdaq.com - August 2 at 6:32 PM
finance.yahoo.com logoNeuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy
finance.yahoo.com - August 2 at 6:32 PM
benzinga.com logoMid-Day Market Update: ShoreTel Gains On Acquisition News ... - Benzinga
www.benzinga.com - July 28 at 7:29 PM
nasdaq.com logoMid-Day Market Update: ShoreTel Gains On Acquisition News; Neuralstem Shares Plunge
www.nasdaq.com - July 27 at 5:59 PM
finance.yahoo.com logoNeuralstem Announces Pricing of Public Offering of Common Stock and Warrants
finance.yahoo.com - July 27 at 5:59 PM
nasdaq.com logoNeuralstem: NSI-189 Phase 2 Trial Fails To Meet Primary Efficacy Endpoint
www.nasdaq.com - July 27 at 2:20 AM
streetinsider.com logoAfter-Hours Movers 07/26: (AXTI) (NTGR) (FB) Higher; (CUR) (CYH) (BWLD) Lower (more...)
www.streetinsider.com - July 27 at 2:20 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Neuralstem and Flex Pharma
finance.yahoo.com - July 26 at 6:13 PM
finance.yahoo.com logoNeuralstem Announces Proposed Public Offering of Common Stock and Warrants
finance.yahoo.com - July 26 at 6:13 PM
rttnews.com logoPositive Data IGNITEs TTPH, MDCO Makes A Good TANGO, Wait Continues For EGRX
www.rttnews.com - July 26 at 3:43 AM
benzinga.com logoMid-Afternoon Market Update: Crude Oil Up 3%; Seagate Shares Drop After Q4 Miss - Benzinga
www.benzinga.com - July 25 at 10:39 PM
marketwatch.com logoUPDATE: Neuralstem stock plummets 61% on news of mid-stage clinical trial miss - MarketWatch
www.marketwatch.com - July 25 at 10:39 PM
finance.yahoo.com logoNeuralstem Announces Top-line Phase 2 Data of NSI-189 for Major Depressive Disorder
finance.yahoo.com - July 25 at 5:37 PM
finance.yahoo.com logoUPDATE: Neuralstem stock plummets 61% on news of mid-stage clinical trial miss
finance.yahoo.com - July 25 at 5:37 PM
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : July 4, 2017
finance.yahoo.com - July 5 at 12:22 AM
finance.yahoo.com logoNeuralstem Added to the Russell Microcap® Index
finance.yahoo.com - June 26 at 5:23 PM
americanbankingnews.com logoNeuralstem, Inc. (CUR) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - June 9 at 3:58 PM
americanbankingnews.com logoNeuralstem, Inc. (CUR) Sees Large Decline in Short Interest
www.americanbankingnews.com - June 3 at 2:20 PM
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : June 2, 2017
finance.yahoo.com - June 2 at 6:04 PM
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : May 23, 2017
finance.yahoo.com - May 23 at 4:22 PM
americanbankingnews.com logoRichard J. Daly Buys 7,500 Shares of Neuralstem, Inc. (CUR) Stock
www.americanbankingnews.com - May 18 at 1:32 PM
streetinsider.com logoNeuralstem (CUR) Completes Dosing in Phase 2 Trial of NSI-189 for Major Depressive Disorder
www.streetinsider.com - May 17 at 9:42 PM
streetinsider.com logoNeuralstem (CUR) Completes Dosing in Phase 2 Trial of NSI-189 for Major Depressive Disorder - StreetInsider.com
www.streetinsider.com - May 17 at 4:41 PM
finance.yahoo.com logoNeuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder
finance.yahoo.com - May 17 at 4:41 PM
finance.yahoo.com logoNeuralstem, Inc. :CUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 5:08 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: MannKind and Neuralstem
finance.yahoo.com - May 11 at 5:14 PM
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 5:14 PM
finanznachrichten.de logoGainers & Losers Of May 10: CUR, TEAR, PRTO, CXRX, DERM...
www.finanznachrichten.de - May 11 at 2:49 AM
americanbankingnews.com logoZacks: Neuralstem, Inc. (CUR) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - May 10 at 8:44 PM
globenewswire.com logoNeuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update
globenewswire.com - May 10 at 4:47 PM
finance.yahoo.com logoNeuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update
finance.yahoo.com - May 10 at 4:47 PM
seekingalpha.com logoNeuralstem, Inc. (CUR)
seekingalpha.com - May 4 at 9:45 PM
americanbankingnews.com logoNeuralstem (CUR) Receiving Positive Press Coverage, Report Finds
www.americanbankingnews.com - April 21 at 6:28 PM
businesswire.com logoBioAxone BioSciences Appoints Dr. Catherine Sohn to Lead Corporate Development
www.businesswire.com - April 20 at 4:45 PM

Social

Chart

Neuralstem (CUR) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff